Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Onyx

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Onyx's 2012 oncology sales performance.

Onyx Pharmaceuticals, Inc.

Deal Watch table for August 2013

Deal Watch table for August 2013 Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

EU nod for Bayer’s Stivarga as Nexavar gets US priority review

EU nod for Bayer’s Stivarga as Nexavar gets US priority review The approvals are also great news for Onyx, which agreed to be taken over by Amgen in a $10.4bn deal earlier this week. ... Onyx earns royalties on sales of Stivarga and Nexavar and has co-promotion rights to Stivarga in the US.

Amgen and Onyx agree $10.4bn takeover deal

Amgen and Onyx agree $10.4bn takeover deal After much horse-trading, the boards of both Amgen and Onyx have added their signatures to a $125-per-share takeover deal. ... sought to gain access to data on Onyx's multiple myeloma drug Kyprolis (carfilzomib).

Bayer gets new Japanese approval for Stivarga

Bayer gets new Japanese approval for Stivarga The drug was originally developed by Onyx and was launched in the US last year for both GIST and CRC. ... it has been predicted to be a $1bn product at peak, with Onyx receiving a 20 per cent royalty on sales.

Pharma deals during July 2013

Pharma deals during July 2013 And rumours continue to circle around the potential acquisitions of Alexion and Onyx.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...